Elafibranor is a dual agonist of the peroxisome proliferator-activated receptor-⍺ and δ (PPAR-⍺ and δ) in Phase III clinical trials for treatment of non-alcoholic steatohepatitis (NASH). Here, we evaluated the drug’s effectiveness in a choline-deficient high fat diet (CDAHFD) NASH model by imaging oxidized collagen as a marker for fibrogenesis in the liver using a Gd-based probe and MRI. Oxidized collagen MRI of the liver showed that Elafibranor successfully reduced fibrogenesis in rats with histologically-confirmed NASH, ex-vivo total collagen quantification by hydroxyproline assay, and histology staining, also confirmed the anti-fibrotic effect of Elafibranor in the CDAHFD-induced NASH model.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords